- A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumorsWu, Lingying; Shen, Lin; Hu, Xichun; Li, Ning; Liu, Dan; Zhang, Jian; Huang, Robert; Teng, Yan; Li, Li; Zhang, Bin; Zhang, Youzhong; Huang, Yi; Wang, Ying; Wu, Junyan; Zheng, Yulong; Luo, Suxia; Ba, Yi; Tong, Zhongsheng; Wang, Xian; Lou, GeAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumorsWu, J.; Zhang, J.; Li, H.; Wang, X.; Zhang, Q. Y.; Shi, Y.; Yan, M.; Pan, Y.; Shen, A.; Chen, Q.; Rao, Q.; Wei, H.; Li, C.; Yang, L.; Huang, Q.; Cao, Z.; Wu, Q.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumorsWang, Yakun; Gong, Jifang; Lin, Rongbo; Zhao, Shen; Wang, Jufeng; Wang, Qianli; Zhang, Yanqiao; Su, Dan; Zhang, Jingdong; Dong, Qian; Lin, Ling; Tian, Wen; Chen, Ying; Yang, Yang; Zhang, Xueyuan; Wan, Xuechao; Gao, Jinfeng; An, Na; Jansen, Valerie Malyvanh; Shen, LinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors
5阅读
